# Part A: In Patients With Chronic Liver Diseases, LAENNEC (Human Placenta Hydrolysate) is to Assess Safety and Tolerability After the Doses of Doses. Part B: Part A, it is to Determine the Optimal Dose by Evaluating Two Capacity and Placebo Groups.

> **NCT05532124** · PHASE2 · COMPLETED · sponsor: **Green Cross Wellbeing** · enrollment: 49 (actual)

## Conditions studied

- Chronic Liver Disease

## Interventions

- **BIOLOGICAL:** LAENNEC (Human Placenta Hydrolysate)
- **OTHER:** normal saline

## Key facts

- **NCT ID:** NCT05532124
- **Lead sponsor:** Green Cross Wellbeing
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-01
- **Primary completion:** 2023-05-25
- **Final completion:** 2023-09-27
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2026-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05532124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05532124, "Part A: In Patients With Chronic Liver Diseases, LAENNEC (Human Placenta Hydrolysate) is to Assess Safety and Tolerability After the Doses of Doses. Part B: Part A, it is to Determine the Optimal Dose by Evaluating Two Capacity and Placebo Groups.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05532124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*